Showing results (1-10 of 77) with videos related to
Sort By:
Pageof 8
Trends in Cancer|May 11, 2020
Managing Cancer Care during the COVID-19 Pandemic and BeyondOmar Alhalabi, Vivek SubbiahAmerican Journal of Cancer Research|January 12, 2022
Truncating <i>CDKN1A</i> mutations: an insight into the biology of urinary tract carcinomas?Omar Alhalabi, Pavlos MsaouelDermatopathology (Basel, Switzerland)|August 10, 2016
Paraneoplastic Dermatosis in a Patient with Anaplastic Large-Cell Lymphoma: Case Report and Literature ReviewTravis Tagami, Omar Alhalabi, Nicholas Ward, et al.Current Opinion in Urology|July 16, 2019
Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histologyOmar Alhalabi, Jose A Karam, Nizar M TannirWorld Journal of Clinical Cases|July 11, 2018
T-cell/histiocyte-rich large B-cell lymphoma in a child: A case report and review of literatureChapman Wei, Chaplin Wei, Omar Alhalabi, et al.Biomedicines|March 28, 2024
Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?Mohammad Jad Moussa, Matthew T Campbell, Omar AlhalabiAdvances in Experimental Medicine and Biology|April 18, 2020
Immunotherapy for MelanomaAya A Albittar, Omar Alhalabi, Isabella C Glitza OlivaCancer Cell|March 21, 2025
Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefitKristen E Pauken, Omar Alhalabi, Sangeeta Goswami, et al.Oncology (Williston Park, N.Y.)|February 8, 2019
Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial CancerOmar Alhalabi, Amishi Y Shah, Emily A Lemke, et al.Cancer Journal (Sudbury, Mass.)|November 16, 2022
Recent Advances in the Development of Antibody-Drug Conjugates in Urothelial CancerOmar Alhalabi, Lina Altameemi, Matthew T Campbell, et al.Pageof 8